Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the Safety and Preliminary Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab in the Treatment of Refractory Familial Cerebral Cavernous Malformations

NCT07026604 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07026604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07026604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the Safety and Preliminary Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab in the Treatment of Refractory Familial Cerebral Cavernous Malformations
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 1, 2025
Completion date
November 1, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cavernous malformation, cerebral